This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01428-06v1 51/5/1844    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Llull, D. Articles by García, E. Search for Related Content PubMed PubMed Citation Articles by Llull, D. Articles by García, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2007, p. 1844-1848, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01428-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Bactericidal Activity of the Antiprotozoal Drug Miltefosine against Streptococcus pneumoniae and Other Pathogenic Streptococci

Departamento de Microbiología Molecular,¹ Departamento de Estructura y Función de Proteínas, Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain²

Received 15 November 2006/ Returned for modification 23 January 2007/ Accepted 3 March 2007

Miltefosine (hexadecylphosphocholine), the first oral drug against visceral leishmaniasis, triggered pneumococcal autolysis at concentrations higher than 2.5 µM. Bactericidal activity was also observed in cultures of other streptococci, although these failed to undergo lysis. The autolysis elicited by miltefosine can be attributed to triggering of the pneumococcal autolysin LytA.

Published ahead of print on 12 March 2007.